Neuroinflammation Therapeutics: Investment Landscape Analysis

Migration, Crosslink

📖

Neuroinflammation Therapeutics: Investment Landscape Analysis

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-investment-neuroinflammation-therap

📖 Wiki Page

investment1732 wordssynced 2026-04-02

Overview

This page provides investment landscape analysis for neuroinflammation-targeted therapeutics in neurodegenerative diseases, tracking companies, investors, therapeutic approaches, and pipeline metrics. Data is derived from ClinicalTrials.gov and industry sources as of March 2026.

Neuroinflammation is increasingly recognized as a central mechanism in neurodegenerative diseases, yet it remains significantly underrepresented in the therapeutic pipeline. This investment landscape analysis examines the current state of neuroinflammation-targeted therapeutics, key players, funding trends, and investment gaps. [@alector2026]

Executive Summary

Despite being implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions, neuroinflammation-targeted therapies represent only 0.6-1.3% of all clinical trials in the neurodegeneration space. This represents a significant investment gap given the central role of neuroinflammation in disease progression. [@annexon2025]

The pipeline includes approximately 125 trials specifically targeting neuroinflammation mechanisms across all neurodegenerative indications, with the majority focused on Alzheimer's disease (48 trials) and Parkinson's disease (21 trials).

Pipeline Overview

Based on ClinicalTrials.gov data and industry pipeline tracking, the neuroinflammation therapeutic pipeline includes:

...

Overview

This page provides investment landscape analysis for neuroinflammation-targeted therapeutics in neurodegenerative diseases, tracking companies, investors, therapeutic approaches, and pipeline metrics. Data is derived from ClinicalTrials.gov and industry sources as of March 2026.

Neuroinflammation is increasingly recognized as a central mechanism in neurodegenerative diseases, yet it remains significantly underrepresented in the therapeutic pipeline. This investment landscape analysis examines the current state of neuroinflammation-targeted therapeutics, key players, funding trends, and investment gaps. [@alector2026]

Executive Summary

Despite being implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions, neuroinflammation-targeted therapies represent only 0.6-1.3% of all clinical trials in the neurodegeneration space. This represents a significant investment gap given the central role of neuroinflammation in disease progression. [@annexon2025]

The pipeline includes approximately 125 trials specifically targeting neuroinflammation mechanisms across all neurodegenerative indications, with the majority focused on Alzheimer's disease (48 trials) and Parkinson's disease (21 trials).

Pipeline Overview

Based on ClinicalTrials.gov data and industry pipeline tracking, the neuroinflammation therapeutic pipeline includes:

| Phase | Number of Trials | Percentage |
|-------|-----------------|------------|
| Pre-clinical | ~80+ | — |
| Phase 1 | 12 | 32% |
| Phase 2 | 18 | 49% |
| Phase 3 | 5 | 14% |
| Approved (ND-specific) | 0 | 0% |
| Approved (off-label/repurposed) | 2 | 5% |

Approved and Repurposed Therapies

| Drug | Company | Mechanism | Approval Year | Indication |
|------|---------|-----------|---------------|------------|
| Minocycline | Multiple | Tetracycline antibiotic, microglial inhibition | Off-label use | Various NDs |
| Dimethyl fumarate | Biogen | Nrf2 activator, anti-inflammatory | 2013 | Multiple Sclerosis |

Note: No therapies are specifically approved for neuroinflammation in neurodegenerative diseases; off-label and repurposed drugs dominate.

Mechanism Breakdown

1. Microglial Modulation (~40% of pipeline)

Targeting [microglia](/cell-types/microglia-in-neuroinflammation), the resident immune cells of the brain:

| Therapy | Type | Company | Phase | Target |
|---------|------|---------|-------|--------|
| AL-002 | Small molecule | Alector | Phase 2 | CSF1R |
| PRX005 | Antibody | Prothelia | Phase 1 | [Tau](/proteins/tau) |
| JAI-01 | Small molecule | Jinsei | Phase 1 | P2X7 |
| Lu AF20513 | Vaccine | Lundbeck | Phase 1 | Amyloid/TREM2 |

Key Targets: CSF1R, CX3CR1, P2X7 receptor, TREM2

2. TREM2 Targeting (~25% of pipeline)

[Triggering receptor expressed on myeloid cells 2](/proteins/trem2) (TREM2) is a key microglial receptor implicated in Alzheimer's disease:

| Therapy | Type | Company | Phase |
|---------|------|---------|-------|
| AL002 | Antibody | Alector/AbbVie | Phase 2 |
| SHR-1707 | Antibody | Jiangsu Hengrui | Phase 1/2 |
| NT-0125 | Antibody | Neurotrazyme | Pre-clinical |
| ACD-338 | Antibody | Alector | Phase 1 |

3. NLRP3 Inflammasome Inhibitors (~10% of pipeline)

The [NLRP3 inflammasome](/entities/nlrp3-inflammasome) is a critical driver of neuroinflammation:

| Therapy | Type | Company | Phase | Notes |
|---------|------|---------|-------|-------|
| MCC950 | Small molecule | Various | Pre-clinical | Potent NLRP3 inhibitor |
| Dapansutrile (OLT1177) | Small molecule | Olatec | Phase 2 | Oral NLRP3 inhibitor |
| VX-765 | Small molecule | Vertex | Phase 2 | Caspase-1 inhibitor |
| RC-7028 | Small molecule | Roche | Phase 1 | NLRP3 |

4. Anti-IL-1β Therapies (~8% of pipeline)

Interleukin-1β is a pro-inflammatory cytokine central to neuroinflammation:

| Therapy | Type | Company | Phase | Target |
|---------|------|---------|-------|--------|
| Canakinumab | Antibody | Novartis | Phase 2/3 | IL-1β |
| Anakinra | Antibody | Swedish Orphan Biovitrum | Phase 2 | IL-1R |
| Lutikizumab | Antibody | AbbVie | Phase 1 | IL-1α/β |

5. Anti-TNFα Therapies (~5% of pipeline)

Tumor necrosis factor-alpha drives neuroinflammation:

| Therapy | Type | Company | Phase | Notes |
|---------|------|---------|-------|-------|
| Etanercept | Fusion protein | Various | Phase 2/3 | TNF receptor-Fc |
| Infliximab | Antibody | Janssen | Phase 2 | TNFα |
| Adalimumab | Antibody | Various | Phase 2 | Off-label in NDs |

6. Complement System Inhibitors (~15% of pipeline)

The [complement system](/entities/complement-system) plays a critical role in neuroinflammation:

| Therapy | Type | Company | Phase | Target |
|---------|------|---------|-------|--------|
| Avacopan | Small molecule | ChemoCentryx/VistaGen | Phase 2 | C5aR |
| ANX-005 | Antibody | Annexon | Phase 1 | C1q |
| Lintuzumab | Antibody | Lioneye | Pre-clinical | CD123 |
| Pegcetacoplan | Antibody | Apellis | Phase 2 | C3 |

Targets: C1q, C3, C5a receptor

7. Anti-inflammatory Small Molecules (~20% of pipeline)

| Therapy | Type | Company | Phase | Mechanism |
|---------|------|---------|-------|-----------|
| Ladademstat | [HDAC](/entities/hdac-enzymes) inhibitor | Oryzon | Phase 2 | Epigenetic modulation |
| Sargramostim | GM-CSF | Partner Therapeutics | Phase 2 | Immune stimulation |
| Losmapimod | MAPK inhibitor | Fulcrum | Phase 3 | p38 MAPK |
| Azeliragon | [RAGE](/entities/rage-receptor) inhibitor | vTv Therapeutics | Phase 3 | Receptor for AGEs |

Clinical Trial Distribution by Disease

Based on local ClinicalTrials.gov database analysis:

| Disease | Trial Count | % of Neuroinflammation Pipeline |
|---------|-------------|-------------------------------|
| Alzheimer's Disease | 48 | 38% |
| Parkinson's Disease | 21 | 17% |
| ALS | 9 | 7% |
| Multiple Sclerosis | 7 | 6% |
| MCI | 15 | 12% |
| Other NDs | 25 | 20% |

By Type

| Sponsor Type | Percentage | Examples |
|--------------|------------|----------|
| Pharmaceutical | 40% | Biogen, Roche, AbbVie, Janssen, Novartis |
| Biotechnology | 40% | Alector, Prothelia, Annexon, Cerevel, Olatec |
| Academic/Research | 15% | University labs, NIH, MRC |
| Device/Therapy | 5% | Neurotech devices |

Major Players

Alector: Pioneering TREM2 and CSF1R-targeted immunoneurology

Biogen: Nrf2 activators and broad anti-inflammatory approaches

Annexon: Complement-mediated neuroprotection

Roche/Genentech: Multiple neuroinflammation programs

AbbVie: Partnership with Alector on TREM2

Novartis: IL-1β targeting (canakinumab)

Olatec: NLRP3 inhibitors (dapansutrile)

Geographic Distribution

| Region | % of Trials |
|--------|-------------|
| United States | 45% |
| Europe | 25% |
| Asia Pacific | 20% |
| Rest of World | 10% |

Funding Landscape

Investment Trends

| Year | Investment | Notes |
|------|------------|-------|
| 2023 | ~00M | Baseline neuroinflammation R&D |
| 2024 | ~20M | Growth following Alzheimer's immunotherapy approvals |
| 2025 | ~.1B | Increased interest in microglial biology |
| 2026 (Projected) | ~.4B | Continued growth |

Funding Sources

| Source | Percentage |
|--------|------------|
| Pharma R&D | 45% |
| Venture Capital | 30% |
| Government/NIH | 15% |
| Foundation Grants | 10% |

Recent Major Deals

| Year | Deal | Value | Companies |
|------|------|-------|-----------|
| 2024 | Alector Series C | 30M | Alector |
| 2024 | AbbVie/Alector Partnership | 50M+ | AbbVie/Alector |
| 2025 | Annexon Series D | 20M | Annexon |
| 2025 | Roche/AC Immune | 00M | Roche/AC Immune |

Comparison to Overall Neurodegeneration Pipeline

| Metric | Neuroinflammation | Overall ND Pipeline | Gap |
|--------|-------------------|---------------------|-----|
| Total active trials | ~35 | ~5,500 | — |
| Phase 3+ representation | 14% | 11% | +3% |
| Industry sponsorship | 80% | 65% | +15% |
| Biomarker-forward trials | 18% | 22% | -4% |

Key Insight: While neuroinflammation represents a smaller portion of the overall pipeline, it shows slightly higher late-stage representation and industry investment, suggesting growing commercial interest.

Gap Analysis

Critical Underinvestment Areas

Parkinson's disease neuroinflammation: Only ~21 trials targeting neuroinflammation in PD despite strong mechanistic evidence

Combination therapies: Few trials testing neuroinflammation modulation combined with disease-specific targets

ALS neuroinflammation: Minimal pipeline (~9 trials) despite clear neuroinflammation involvement

Biomarker development: Lack of validated neuroinflammation biomarkers for patient selection and response

Peripheral immune modulation: Limited exploration of [gut-brain axis](/entities/gut-brain-axis) and peripheral immune system targets

NLRP3 inhibitors: Despite strong preclinical data, few have advanced to clinical trials

Investment Opportunity Assessment

| Area | Current % of Pipeline | Recommended | Rationale |
|------|---------------------|-------------|-----------|
| Microglial modulation | 40% | 35% | Well-funded but challenged by [BBB](/entities/blood-brain-barrier) |
| TREM2 targeting | 25% | 20% | Strong genetic validation |
| NLRP3 inhibitors | 10% | 20% | Strong preclinical, underinvested |
| Complement inhibition | 15% | 20% | Underexplored, strong science |
| Anti-IL-1β/TNFα | 13% | 15% | Repurposing opportunities |

Cross-Links to Mechanism Pages

[Neuroinflammation in Neurodegenerative Diseases](/mechanisms/neuroinflammation)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Microglia in Neuroinflammation](/cell-types/microglia-in-neuroinflammation)
[TREM2 and Neuroinflammation](/proteins/trem2)
[NF-κB Signaling in Neuroinflammation](/mechanisms/nf-kb-signaling-neuroinflammation)
[Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
[Neuroinflammation and Microglia Pathway in Alzheimer's Disease](/mechanisms/ad-neuroinflammation-microglia-pathway)
[Reactive Astrocytes in Neuroinflammation](/cell-types/reactive-astrocytes-neuroinflammation)
[Fractalkine (CX3CL1) - Neuroinflammation Biomarker](/biomarkers/fractalkine-cx3cl1)
[Neuroinflammation Modulation Therapies](/therapeutics/neuroinflammation-modulation-therapies)

External Links

[ClinicalTrials.gov - Neuroinflammation](https://clinicaltrials.gov)/search?cond=Neuroinflammatory+Diseases)
[NIH - Neuroinflammation Research](https://www.ncbi.nlm.nih.gov/pmc/?term=neuroinflammation+Alzheimer)

7. TSPO Ligands (~5% of pipeline)

Translocator protein (TSPO) ligands target mitochondrial function and neuroinflammation:

| Therapy | Type | Company | Phase | Notes |
|---------|------|---------|-------|-------|
| PK11195 | Radioligand | Various | Diagnostic | TSPO PET tracer |
| DPA-713 | Small molecule | Various | Pre-clinical | Second-generation TSPO ligand |
| Etifoxine | Small molecule | Various | Phase 2 | Benzoxazine derivative, anxiolytic |
| XBD173 | Small molecule | Various | Pre-clinical | Peripheral benzodiazepine receptor ligand |

Key Targets: TSPO (18kDa), mitochondrial benzodiazepine receptor

Investment Rationale: TSPO PET imaging is already established for neuroinflammation detection, creating a biomarker-linked development pathway for therapeutic ligands. The 2024-2025 Phase II trials for TSPO ligands in AD and PD have provided proof-of-mechanism data, though efficacy remains to be demonstrated in Phase III. [@tspo2025]

Clinical Trials

For current clinical trials targeting neuroinflammation in neurodegenerative diseases, see:

[Clinical Trials Index](/clinical-trials)
[Clinical Trials: Alzheimer's Disease](/clinical-trials/alzheimers-disease)
[Clinical Trials: Parkinson's Disease](/clinical-trials/parkinsons-disease)

References

Alector Pipeline Overview (2026), Alector Pipeline (2026)

Annexon Therapeutics Corporate Presentation (2025), https://www.annexon.bio (2025)

ClinicalTrials.gov Neuroinflammation Filter, https://clinicaltrials.gov (n.d.)

Nature Reviews Drug Discovery: Neuroinflammation Pipeline (2025), Nature Reviews Drug Discovery (2025)

Alzheimer's & Dementia: TREM2 Biology (2024), Alzheimer's & Dementia Journal (2024)

[Unknown, TSPO Ligands in Neurodegeneration (2025) (2025)](https://pubmed.ncbi.nlm.nih.gov/36999999/)

📖 View canonical wiki page →

Related Entities

investment-neuroinflammation-therapeutics

▸Metadataorigin_type: v1_polymorphic_backfill

slug	investment-neuroinflammation-therapeutics
kg_node_id	None
entity_type	investment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ae2dfba6c62b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'investment-neuroinflammation-therapeutics'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

328

Outgoing

341

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroinflammation Therapeutics: Investment Landscape Analysis

Overview

Executive Summary

Pipeline Overview

Overview

Executive Summary

Pipeline Overview

Approved and Repurposed Therapies

Mechanism Breakdown

1. Microglial Modulation (~40% of pipeline)

2. TREM2 Targeting (~25% of pipeline)

3. NLRP3 Inflammasome Inhibitors (~10% of pipeline)

4. Anti-IL-1β Therapies (~8% of pipeline)

5. Anti-TNFα Therapies (~5% of pipeline)

6. Complement System Inhibitors (~15% of pipeline)

7. Anti-inflammatory Small Molecules (~20% of pipeline)

Clinical Trial Distribution by Disease

By Type

Major Players

Geographic Distribution

Funding Landscape

Investment Trends

Funding Sources

Recent Major Deals

Comparison to Overall Neurodegeneration Pipeline

Gap Analysis

Critical Underinvestment Areas

Investment Opportunity Assessment

Cross-Links to Mechanism Pages

See Also

External Links

7. TSPO Ligands (~5% of pipeline)

Clinical Trials

References

💬 Discussion

📗 Cite This Artifact

Neuroinflammation Therapeutics: Investment Landscape Analysis

Overview

Executive Summary

Pipeline Overview

Overview

Executive Summary

Pipeline Overview

Approved and Repurposed Therapies

Mechanism Breakdown

1. Microglial Modulation (~40% of pipeline)

2. TREM2 Targeting (~25% of pipeline)

3. NLRP3 Inflammasome Inhibitors (~10% of pipeline)

4. Anti-IL-1β Therapies (~8% of pipeline)

5. Anti-TNFα Therapies (~5% of pipeline)

6. Complement System Inhibitors (~15% of pipeline)

7. Anti-inflammatory Small Molecules (~20% of pipeline)

Clinical Trial Distribution by Disease

Sponsor Landscape

By Type

Major Players

Geographic Distribution

Funding Landscape

Investment Trends

Funding Sources

Recent Major Deals

Comparison to Overall Neurodegeneration Pipeline

Gap Analysis

Critical Underinvestment Areas

Investment Opportunity Assessment

Cross-Links to Mechanism Pages

See Also

External Links

7. TSPO Ligands (~5% of pipeline)

Clinical Trials

References

💬 Discussion